A proven roadmap for innovation and commercialization

We empower inventors — paving pathways, clearing obstacles and dedicating significant resources to technology transfer.

Impact Dashboard

251

FY22 Invention Disclosures

79

FY22 U.S. Patents Issued

$14.6M

FY22 Licensing Revenue

7

FY22 New IP Based Startups

This is WashU Innovation

The Office of Technology Management assists WashU faculty in the transfer of technology from the lab to the global marketplace.

Explore our innovation community

Needlemans commit $15 million to boost drug discovery

A generous gift from longtime benefactors of Washington University School of Medicine in St. Louis establishes the Needleman Program for Innovation and Commercialization. For a select number of projects, the new program will provide funding to help move promising therapeutics towards the stage where the Food and Drug Administration grants investigational new drug (IND) status.

EMBA alum’s startup wins $250K in Texas competition

June 5, 2023

A WashU-based life sciences startup that patented a groundbreaking bloodstream marker that flags potential cardiovascular disease recently won a $250,000 investment prize in a major national pitch competition.

Wearable, light-based brain-imaging tech to be commercialized with aid of NIH grant

May 25, 2023

Wearable brain-imaging tech aims to reveal how the brain works in natural, realistic situations. Washington University faculty members Joseph P. Culver, Jason Trobaugh and Ed Richter, along with Adam Eggebrecht, have received a grant from the NIH to develop and commercialize a brain-imaging cap that uses LED light to gauge brain activity.

Findings may lead to improved insulin-secreting cells derived from stem cells

May 17, 2023

Diabetes researchers at Washington University School of Medicine in St. Louis have uncovered at least one reason insulin-secreting cells made from stem cells in the lab don’t work as well as natural cells. The discovery could help speed progress toward making insulin-secreting cells — called islet beta cells — more effective in the treatment of insulin-dependent Type 1 diabetes.


Announcements

Resources for Students & Alumni

The Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship serves as the primary resource for students and alumni.